However, pioglitazone (an anti-diabetic medication) (18, 19), and Glucagon-like peptide-1 (GLP-1) receptor agonists (20, 21) have shown promising hepatic outcomes in patients with MASLD. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.